[Summary] Developer of small nucleic acid drugs for hepatitis B
Haobo Pharmaceutical is a biopharmaceutical company dedicated to advancing oligonucleotide (small nucleic acid) drug innovation, starting with the goal of curing hepatitis B and committed to bringing transformative therapeutic solutions to patients worldwide.
As a leader in the third wave of biopharmaceuticals following small molecules and antibodies, Haobo Pharmaceutical has built a complete closed-loop system spanning target discovery, sequence design, process development, clinical development, and commercialization, leveraging its proprietary Med-Oligo™ technology platform and targeted delivery system. We not only focus on curing hepatitis B but have also extended our technology to multiple disease areas such as metabolic, genetic, and immune diseases, driving a paradigm shift in treatment from "long-term control" to "finite-course cure."
AHB-137, our core product, is one of the company's key pipelines in the field of hepatitis B cure. In 2024, it received "Breakthrough Therapy" designation from the National Medical Products Administration. Its Phase IIa data showed that AHB-137 monotherapy achieved a breakthrough 30% clinical cure rate in chronic hepatitis B patients after a 24-week treatment course. Enrollment for its Phase III clinical trial in mainland China has been completed, and multiple global Phase II clinical trials are progressing simultaneously.
Haobo Pharmaceutical has a first-class new drug R&D team with extensive operational experience. The core founder team were key leaders of the global team that developed breakthrough curative drugs for hepatitis C, bringing nearly two decades of successful R&D leadership philosophy and experience from multiple blockbuster drugs at Gilead Sciences in the United States. They successfully led the complete development of blockbuster drugs including Harvoni (annual sales exceeding ten billion US dollars), Epclusa (annual sales of several billion US dollars), and Biktarvy (all of which have been included in the national medical insurance scheme).
In 2026, as multiple platform pipelines enter clinical stages and core products move toward commercialization, Haobo Pharmaceutical is accelerating the construction of a full-chain innovation system from R&D to clinical development to commercialization, promoting the cluster development of China's small nucleic acid industry. We look forward to working with you to realize the vision of "from Chinese innovation to global accessibility."
For more information, please visit *.
What does Hangzhou Haobo Pharmaceutical Co., Ltd. require? Who is Haobo Pharmaceutical hiring? Haobo Pharmaceutical recruitment: 医疗卫生/美容保健类占比最多占55.6%,其次是生物/制药/化工/环保类占22.2%. What education can get in at Haobo Pharmaceutical? 本科占比最多占55.6%,其次是硕士占27%. High education required at Haobo Pharmaceutical? 硕士占27%,博士占1.6%. Work experience required at Haobo Pharmaceutical? 5-10年占比最多占42.9%,其次是1-3年占25.4%. Where are the job locations at Haobo Pharmaceutical? 杭州占比最多占98.4%,其次是北京占1.6%. Based on job postings from the past year, for reference only.
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows